PremiumCompany AnnouncementsAmwell Reports Strong Q1 2025 Financial Results Hold Rating Maintained for American Well Amid Revenue Growth and Contract Uncertainties Amwell backs FY25 revenue view $250M-$260M, consensus $255.06M Telehealth companies aggressively marketing hair-loss medicine to men, WSJ says Amwell Appoints Dan Zamansky as New CTO PremiumThe FlyAmwell price target raised to $10 from $9 at Stifel Strong Revenue Performance and Strategic Growth: Justifying the Buy Rating for American Well Hold Rating for American Well Amid Mixed Financial Outlook and Strategic Shifts 
